Clinical outcome and safety of rituximab therapy for pemphigoid diseases
Published: 19 February 2020| Version 1 | DOI: 10.17632/7j5vv3rryc.1
Contributors:
, Description
https://doi.org/10.1016/j.jaad.2019.11.023 Supplemental materials for this retrospective case series including all (n=38) pemphigoid patients at the University of Pennsylvania followed at least 1 year after RTX or until death. Outcomes followed consensus definitions. The primary endpoint was complete remission (CR). Secondary endpoints were CR off therapy (CROT), corticosteroid dose, relapse, serious adverse events (SAEs), and autoantibody titers.
Files
Institutions
University of Pennsylvania
Categories
Autoimmunity, Rituximab, Pemphigoid